Pheochromocytoma medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:


==Medical Therapy==
==Medical Therapy==
'''Preoperative medical therapy:'''
All patients doing surgery need preoperative treatment to control hypertension during surgery and hypotension after it. There are three medical regimens for treatment; Combined alpha and beta-adrenergic blockade, calcium channel blockers, and metyrosine.<ref name="pmid14766711">{{cite journal| author=Tauzin-Fin P, Sesay M, Gosse P, Ballanger P| title=Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. | journal=Br J Anaesth | year= 2004 | volume= 92 | issue= 4 | pages= 512-7 | pmid=14766711 | doi=10.1093/bja/aeh083 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14766711  }}</ref>
Any surgical option requires prior treatment with both the non-selective [[alpha blocker|alpha adrenoceptor blocker]] ([[phenoxybenzamine]]) to counteract [[hypertension]] and the beta-1 adrenoceptor antagonist [[atenolol]] to reduce [[cardiac output]]. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour resection, which would otherwise endanger the anaesthetised patient.
Any surgical option requires prior treatment with both the non-selective [[alpha blocker|alpha adrenoceptor blocker]] ([[phenoxybenzamine]]) to counteract [[hypertension]] and the beta-1 adrenoceptor antagonist [[atenolol]] to reduce [[cardiac output]]. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour resection, which would otherwise endanger the anaesthetised patient.


TREATMENT — Once a pheochromocytoma is diagnosed, the patient should undergo surgery after appropriate medical preparation. Preoperative resolution of symptoms and normalization of blood pressure are predictors of an uncomplicated outcome [63].
Medical preparation for surgery — No universally accepted method of preparation for surgery in children with pheochromocytomas has been established. In our practice we generally use alpha-adrenergic blockade with phenoxybenzamine(Dibenzyline) [10]. some clinicians may choose to a selective alpha-1 antagonist (eg, doxazosin, terazosin, prazosin).
 
Medical preparation for surgery — No universally accepted method of preparation for surgery in children with pheochromocytomas has been established. In our practice we generally use alpha-adrenergic blockade with phenoxybenzamine(Dibenzyline) unless contraindicated because of cardiopulmonary concerns. The starting dose of phenoxybenzamine in children is 0.25 to 1.0 mg/kg per day or 10 mg once daily; the dose is increased every few days until the patient's symptoms and blood pressure are controlled [10]. Due to increases in the cost of phenoxybenzamine, some clinicians may choose to a selective alpha-1 antagonist (eg, doxazosin, terazosin, prazosin).


On the second or third day of alpha-adrenergic blockade, patients are encouraged to start a diet high in sodium content because of the catecholamine-induced volume contraction and the orthostasis associated with alpha-adrenergic blockade. This causes intravascular volume expansion, which may be contraindicated in patients with heart failure or renal insufficiency.
On the second or third day of alpha-adrenergic blockade, patients are encouraged to start a diet high in sodium content because of the catecholamine-induced volume contraction and the orthostasis associated with alpha-adrenergic blockade.


After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is initiated, which typically occurs two to three days preoperatively. The beta-adrenergic blocker should never be started first, because blockade of vasodilatory peripheral beta-adrenergic receptors with unopposed alpha-adrenergic receptor stimulation can lead to a further elevation in blood pressure. The clinician should exercise caution if the patient is asthmatic or has heart failure. Chronic catecholamine excess can produce a cardiomyopathy that may become evident with the initiation of beta-adrenergic blockade, resulting in acute pulmonary edema. Therefore, when the beta-adrenergic blocker is administered, it should be used cautiously and at a low dose. The dose is then increased as necessary to control the tachycardia. In most cases, the patient is ready for surgery in 10 to 14 days after starting the alpha-adrenergic blockade.
After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is initiated, which typically occurs two to three days preoperatively. The beta-adrenergic blocker should never be started first, because blockade of vasodilatory peripheral beta-adrenergic receptors with unopposed alpha-adrenergic receptor stimulation can lead to a further elevation in blood pressure. The clinician should exercise caution if the patient is asthmatic or has heart failure. Chronic catecholamine excess can produce a cardiomyopathy that may become evident with the initiation of beta-adrenergic blockade, resulting in acute pulmonary edema. Therefore, when the beta-adrenergic blocker is administered, it should be used cautiously and at a low dose. The dose is then increased as necessary to control the tachycardia. the patient is ready for surgery in 10 to 14 days after starting the alpha-adrenergic blockade.


Although perioperative alpha blockade is widely recommended, a second regimen that has been utilized in adults at the Cleveland Clinic and France involves the administration of a calcium channel blocker for blood pressure control [64,65]. In a review of 113 adult patients who underwent removal of pheochromocytomas, fewer perioperative complications were observed in those not given alpha-adrenergic antagonists [64]. (See "Treatment of pheochromocytoma in adults", section on 'Calcium channel blockers'.)
administration of a calcium channel blocker for blood pressure control 64,65


A third approach is to administer metyrosine (alpha-methyl-para-tyrosine), which inhibits catecholamine synthesis by blocking the enzyme tyrosine hydroxylase. Metyrosine should be used with caution and only when other agents have been ineffective or if significant tumor manipulation is anticipated. Although some centers have used this agent routinely, most clinicians reserve metyrosine primarily for patients who cannot be treated with the combined alpha and beta-adrenergic blockade protocol because of intolerance or cardiopulmonary concerns. The starting dose of metyrosine in children is 125 mg (250 capsules can be reduced to 125 mg capsules by a pharmacist) once or twice daily, with an increase in dose as required or based on a target decline in fractionated metanephrines and catecholamines (unpublished personal experience). The use of metyrosine has also become more problematic because of increases in cost. (See "Treatment of pheochromocytoma in adults", section on 'Metyrosine'.)
most clinicians reserve metyrosine primarily for patients who cannot be treated with the combined alpha and beta-adrenergic blockade protocol because of intolerance or cardiopulmonary concerns. The use of metyrosine has also become more problematic because of increases in cost.


===Chemotherapy===
===Chemotherapy===

Revision as of 13:23, 5 July 2017

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma medical therapy

CDC on Pheochromocytoma medical therapy

Pheochromocytoma medical therapy in the news

Blogs on Pheochromocytoma medical therapy

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Treatment with alpha blockers (example: phenoxybenzamine) followed by beta blockers (example: atenolol) is required before surgery. Adjunctive chemotherapy and radiation are used in metastatic disease.

Medical Therapy

Preoperative medical therapy:

All patients doing surgery need preoperative treatment to control hypertension during surgery and hypotension after it. There are three medical regimens for treatment; Combined alpha and beta-adrenergic blockade, calcium channel blockers, and metyrosine.[1]

Any surgical option requires prior treatment with both the non-selective alpha adrenoceptor blocker (phenoxybenzamine) to counteract hypertension and the beta-1 adrenoceptor antagonist atenolol to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour resection, which would otherwise endanger the anaesthetised patient.

Medical preparation for surgery — No universally accepted method of preparation for surgery in children with pheochromocytomas has been established. In our practice we generally use alpha-adrenergic blockade with phenoxybenzamine(Dibenzyline) [10]. some clinicians may choose to a selective alpha-1 antagonist (eg, doxazosin, terazosin, prazosin).

On the second or third day of alpha-adrenergic blockade, patients are encouraged to start a diet high in sodium content because of the catecholamine-induced volume contraction and the orthostasis associated with alpha-adrenergic blockade.

After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is initiated, which typically occurs two to three days preoperatively. The beta-adrenergic blocker should never be started first, because blockade of vasodilatory peripheral beta-adrenergic receptors with unopposed alpha-adrenergic receptor stimulation can lead to a further elevation in blood pressure. The clinician should exercise caution if the patient is asthmatic or has heart failure. Chronic catecholamine excess can produce a cardiomyopathy that may become evident with the initiation of beta-adrenergic blockade, resulting in acute pulmonary edema. Therefore, when the beta-adrenergic blocker is administered, it should be used cautiously and at a low dose. The dose is then increased as necessary to control the tachycardia. the patient is ready for surgery in 10 to 14 days after starting the alpha-adrenergic blockade.

administration of a calcium channel blocker for blood pressure control 64,65

most clinicians reserve metyrosine primarily for patients who cannot be treated with the combined alpha and beta-adrenergic blockade protocol because of intolerance or cardiopulmonary concerns. The use of metyrosine has also become more problematic because of increases in cost.

Chemotherapy

Metastatic pheochromocytoma is treated with Averbuc protocol which is a combination of cyclophosphamide, vincristine, and dacarbazine.[2]

Radiation

131I-MIBG radiation therapy has been used for the treatment of MIBG-avid metastases.[2]

Contraindicated medications

Pheochromocytoma is considered an absolute contraindication to the use of the following medications:

References

  1. Tauzin-Fin P, Sesay M, Gosse P, Ballanger P (2004). "Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma". Br J Anaesth. 92 (4): 512–7. doi:10.1093/bja/aeh083. PMID 14766711.
  2. 2.0 2.1 National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_179_toc

Template:WS Template:WH